Sociodemographic and clinical history data of the patients included in the study
| % (n) or mean (95% CI) N=126 | ||
| Age | 61.5 (95% CI 59.4 to 63.7) | |
| Age groups | ≤65 years | 57.9% (73) |
| >65 ≤75 years | 31% (39) | |
| >75 years | 11.1% (14) | |
| Gender | Male | 58.7% (74) |
| Female | 41.3% (52) | |
| Race | Caucasian | 99.2% (125) |
| Black | 0.8% (1) | |
| Socioeconomic level | Low | 17.5% (22) |
| Middle | 71.4% (90) | |
| High | 11.1% (14) | |
| Body mass index (BMI), kg/m2 | 25 (24.2–25.8) | |
| Classification according to BMI | Cachexia (<20 kg/m2) | 10.3% (13) |
| Normal (≥20 to <25 kg/m2) | 42.9% (54) | |
| Overweight (≥25 to <30 kg/m2) | 35.7% (45) | |
| Obese (≥30 kg/m2) | 11.1% (14) | |
| Karnofsky performance status (%) | 77.5 (95% CI 75.4 to 79.7) | |
| Patients with system organ class disorders on treatment at study entry | Blood and lymphatic system | 4.8% (6) |
| Cardiac | 25.4% (32) | |
| Endocrine | 15.1% (19) | |
| Gastrointestinal | 5.6% (7) | |
| Musculoskeletal and connective | 19% (24) | |
| Neoplasms | 88.9% (112) | |
| Nervous system | 2.4% (3) | |
| Psychiatric | 10.3% (13) | |
| Renal and urinary | 11.1% (14) | |
| Respiratory | 16.7% (21) | |
| Skin and subcutaneous tissue | 2.4% (3) | |
| Organ affected by the cancer | Lung | 35.7% (45) |
| Breast | 16.7% (21) | |
| Gastrointestinal | 10.3% (13) | |
| Prostate | 8.7% (11) | |
| Other | 28.6% (36) | |
| Time from cancer diagnosis (months) | 34.7 (95% CI 23.5 to 45.9) | |
| Presence of metastases | 67.5% (85) | |